BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal
Written by
BioPharma Dive
Published
0
comments
0
min
The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an acquisition of its one-time COVID-19 vaccine competitor.